Glaukos Corp
Change company Symbol lookup
Select an option...
GKOS Glaukos Corp
WWR Westwater Resources Inc
AGNPF Algernon Pharmaceuticals Inc
VNTR Venator Materials PLC
DVAX Dynavax Technologies Corp
GE General Electric Co
GTPBU Gores Technology Partners II Inc
IRBT iRobot Corp
NRG NRG Energy Inc
FRLAU Fortune Rise Acquisition Corp
Go

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. It is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants that are designed to elute pharmaceuticals.

Closing Price
$50.25
Day's Change
-0.14 (-0.28%)
Bid
--
Ask
--
B/A Size
--
Day's High
51.39
Day's Low
49.69
Volume
(Light)
Volume:
382,169

10-day average volume:
591,775
382,169

Company Profile

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. It is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants that are designed to elute pharmaceuticals.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
8.32x
Price/Book (MRQ)
4.25x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

August 2022
Current Month
2.5M
Previous Month
1.6M
Percent of Float
5.58%
Days to Cover
6.2548 Days

Share Information

GKOS is in a share class of common stock
Float
45.7M
Shares Outstanding
47.6M
Institutions Holding Shares
260
92.17%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Thomas William BurnsChmn.
  • Joseph E. GilliamPres.
  • Alex R. ThurmanCFO
  • Tomas NavratilOther
  • Mark J. Foley

Address

Insider Trading

During the most recent quarter, 3K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.